|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 9700 W. BRYN MAWR AVENUE |
Address2 |
|
| City | ROSEMONT |
State | IL |
Zip Code | 60018-5701 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1672-24
|
||||||||
|
6. House ID# 317140000
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Jeanne Tuerk |
Date | 4/20/2026 2:22:46 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services
Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state.
Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sandra |
Guenther |
|
|
|
Jeanne |
Tuerk |
|
|
|
Karin |
Wittich |
|
|
|
Srini |
Varadarajan |
|
|
|
Lauren |
Wright |
|
|
|
Paula |
Kantas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code EDU
16. Specific lobbying issues
Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency.
Comments on the Reimagining and Improving Student Education Notice of Proposed Rulemaking; RIN 1840-AD98
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Education - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sandra |
Guenther |
|
|
|
Jeanne |
Tuerk |
|
|
|
Karin |
Wittich |
|
|
|
Srini |
Varadarajan |
|
|
|
Lauren |
Wright |
|
|
|
Paula |
Kantas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Support for legislative efforts to provide long term reform to the Medicare physician payment system as well as repeal the 2.5 precent efficiency cut scheduled for CY 2026.
Comments in response to the proposed rule, Patient Protection and Affordable Care Act (ACA); Notice of Benefit and Payment Parameters for 2027 that opposes reinstating the prohibition on non-pediatric dental services as an essential health benefit.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Tuerk |
|
|
|
Karin |
Wittich |
|
|
|
Sandy |
Guenther |
|
|
|
Srini |
Varadarajan |
|
|
|
Paula |
Kantas |
|
|
|
Lauren |
Wright |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
-Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages.
-Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks.
-Support for the Drug Shortages Prevention Act (S 2665), which would have required
manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages
-Support for the reintroduction of the following bill from the 118th Congress:
The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications
-Comments in response to the notice of proposed rulemaking (ANPRM) Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals.
-Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP).
-Support for FY 2027 appropriations for the Dr. Lorna Breen Health Care Provider Protection Act.
-Support for the Alternatives to Prevent Addiction in the Nation Act (H.R. 1227), which would reduce cost-sharing and prohibits the imposition of certain utilization requirements under the Medicare prescription drug benefit for certain non-opioid pain management drugs.
-Urging CMS to communicate to Part D plan sponsors about the clinical importance of FDA-approved, clinically appropriate non-opioid acute pain treatment options and encourage appropriate formulary coverage ensuring beneficiary access to such approaches.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Defense - Dept of (DOD), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Tuerk |
|
|
|
Srini |
Varadarajan |
|
|
|
Karin |
Wittich |
|
|
|
Sandra |
Guenther |
|
|
|
Lauren |
Wright |
|
|
|
Paula |
Kantas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |